Identification and Characterization of a Novel Fosfomycin Bacillithiol Transferase FosB8 in Paenibacillus illinoisensis
This study identifies and characterizes FosB8, a novel intrinsic fosfomycin bacillithiol transferase in *Paenibacillus illinoisensis* that confers high-level resistance through efficient enzymatic detoxification, marking it as the eighth known member of the FosB enzyme family.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the ongoing battle between medicine and microscopic life, bacteria have a long history of learning to survive the drugs designed to kill them. One such drug, fosfomycin, is an older antibiotic that doctors sometimes turn to when newer medicines fail, particularly for infections in the urinary tract or when dealing with stubborn, multi-drug-resistant bacteria. The drug works by attacking a specific step bacteria need to build their cell walls, essentially stopping them from growing. However, some bacteria have developed a clever defense mechanism: they produce a special enzyme that acts like a molecular pair of scissors, cutting the drug apart before it can do its job. This process, known as inactivation, renders the medicine useless. While scientists have known about several versions of these defensive enzymes in common bacteria like Staphylococcus, there are many less common bacteria that remain poorly understood, leaving a gap in our knowledge of how resistance spreads in the wider microbial world.
Researchers recently turned their attention to a rare bacterium called Paenibacillus illinoisensis, which was isolated from the wound of an elderly patient in a hospital in Hangzhou, China. This specific strain, named WP77, was found to be resistant to fosfomycin, but the genetic reason for this resistance was a mystery. Standard genetic searches failed to find any of the known resistance genes that usually explain such immunity. To solve this puzzle, the team sequenced the entire genetic code of the bacterium and began a detailed hunt for the hidden mechanism. They discovered a new gene, which they named fosB8, that had never been seen before in this specific form. This gene encodes a protein that functions as a fosfomycin bacillithiol transferase, a type of enzyme that chemically modifies the antibiotic to neutralize it. The researchers confirmed that this new gene was indeed the cause of the resistance by inserting it into a harmless laboratory bacterium, which then became highly resistant to the drug, just like the original patient isolate.
The study provided a close look at how this new enzyme works. The team purified the protein produced by the fosB8 gene and tested its activity in a controlled environment. They found that the enzyme efficiently attaches a small molecule called bacillithiol to the fosfomycin drug, breaking the drug's structure and rendering it harmless. While this new enzyme was slightly less efficient at this task than a previously known version found in Staphylococcus, it was still powerful enough to protect the bacteria completely. When the researchers tested the bacteria carrying this new gene, the amount of drug needed to stop their growth increased by a factor of 256 compared to bacteria without the gene. This dramatic jump confirmed that the gene was the primary reason the original bacterium could survive the treatment.
Beyond just identifying the gene, the researchers mapped out its surroundings within the bacterial genome to understand how it might spread. They found that the fosB8 gene sits on the main chromosome of the bacterium, rather than on a small, movable ring of DNA called a plasmid, which is often how resistance genes jump between different species. The area around the gene did not show signs of the usual mobile genetic elements that facilitate rapid transfer. However, the researchers noted that this specific gene appears to be naturally present in many different strains of Paenibacillus, suggesting that this genus of bacteria might act as a natural reservoir, holding onto this resistance trait over long periods. The study also revealed that the bacterium's genome is about 6.64 million base pairs long and contains nearly 6,000 genes, providing a complete genetic blueprint for this rare organism.
The discovery of fosB8 is significant because it represents the eighth known type of this specific resistance enzyme, expanding the catalog of ways bacteria can defeat antibiotics. The researchers confirmed that the enzyme is specific to fosfomycin and does not confer resistance to other types of antibiotics like tetracycline or gentamicin. This specificity helps explain why the bacterium is resistant to some drugs but remains vulnerable to others. The study concludes that while this resistance gene is currently found on the chromosome and may not be spreading rapidly between different species, its presence in a wide variety of Paenibacillus strains means it could potentially be transferred to more dangerous pathogens in the future. By characterizing this new enzyme and its genetic home, the study provides a clearer picture of the hidden defenses bacteria possess, offering a better foundation for understanding how resistance evolves and persists in clinical settings.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.